XRCC1 Genetic Polymorphism Arg399Gln and Prostate Cancer Risk: A Meta-analysis - 06/08/11

Résumé |
Objectives |
To evaluate the association between x-ray cross-complementing gene 1 (XRCC1) genetic polymorphism Arg399Gln and prostate cancer risk using a meta-analysis.
Methods |
A comprehensive search was conducted to identify all case-control studies of XRCC1 Arg399Gln polymorphism and prostate cancer risk. Statistical analysis was performed using the software program Review Manage, version 4.2, and STATA, version 8.0.
Results |
We identified 7 eligible reports, 1733 prostate cancer cases, and 1756 controls. No significant associations were observed between XRCC1 Arg399Gln polymorphism and the risk of prostate cancer in worldwide populations, without any between-study heterogeneity. In the stratified analysis by ethnicity, our results indicated a significant association and recessive genetic mode of XRCC1 Arg399Gln polymorphism with prostate cancer risk in Asian subjects. Asians with the variant Gln/Gln allele were about 43% more likely to have prostate cancer than were those with the genotype Arg/Gln or Arg/Arg. However, our results also suggested that XRCC1 Arg399Gln polymorphism was not significantly associated with prostate cancer in white men.
Conclusions |
The results of the present meta-analysis have indicated that the XRCC1 codon 399 Gln allele might act as a recessive allele in its association with prostate cancer risk in Asians only.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by grant 30872979 from the National Natural Science Foundation of China. |
Vol 74 - N° 3
P. 648-653 - septembre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
